Kepler Cheuvreux Suisse SA Purchases New Holdings in Johnson & Johnson $JNJ

Kepler Cheuvreux Suisse SA acquired a new position in Johnson & Johnson (NYSE:JNJ) during the 3rd quarter, HoldingsChannel reports. The fund acquired 83,324 shares of the company’s stock, valued at approximately $15,448,000.

Other hedge funds have also made changes to their positions in the company. Abich Financial Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth approximately $26,000. Evolution Wealth Management Inc. acquired a new position in Johnson & Johnson in the 2nd quarter valued at $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at $28,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc boosted its stake in Johnson & Johnson by 707.1% during the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after purchasing an additional 198 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approved the combination of TECVAYLI (teclistamab‑cqyv) plus DARZALEX FASPRO for relapsed/refractory multiple myeloma, supported by Phase‑3 MajesTEC‑3 data showing improved progression‑free and overall survival — a meaningful commercial and clinical win that can expand J&J’s oncology revenue and shift treatment patterns earlier in the therapy line. How FDA Approval of TECVAYLI and DARZALEX FASPRO Combo At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: EU expanded approval of Akeega to include BRCA‑mutated metastatic hormone‑sensitive prostate cancer — label expansion that can broaden addressable market in oncology and supports incremental sales in EMEA. JNJ Gets EU Nod for Expanded Use of Akeega in Prostate Cancer
• Neutral Sentiment: Management’s presentation at the Barclays Global Healthcare Conference provides updated commentary on pipeline priorities and commercialization plans — useful for tracking execution but not a discrete catalyst by itself. Johnson & Johnson (JNJ) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Analyst/valuation pieces and recent share‑price momentum have revived investor attention — this could sustain trading interest but depends on execution and revenue contribution from recent approvals. Assessing Johnson & Johnson (JNJ) Valuation As Recent Share Moves Revive Investor Interest
• Negative Sentiment: Short interest rose ~20.8% in February to ~25.09M shares (≈1.0% of shares), raising the short‑interest ratio to ~2.5 days — a small bearish signal that can add volatility if sentiment turns.
• Negative Sentiment: Two J&J units agreed to pay about $65M to settle a Tracleer antitrust class action — a modest cash cost relative to J&J’s size but a legal/expense item to note. Johnson & Johnson (JNJ) Units to Pay $65 Million in Tracleer Antitrust Class Action Settlement, Reuters Reports

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last 90 days. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.5%

NYSE JNJ opened at $243.75 on Wednesday. The business’s fifty day simple moving average is $229.80 and its 200-day simple moving average is $205.27. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market cap of $587.41 billion, a PE ratio of 22.06, a P/E/G ratio of 2.40 and a beta of 0.34. Johnson & Johnson has a 52 week low of $141.50 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Citigroup increased their target price on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. TD Cowen increased their price objective on shares of Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Rothschild & Co Redburn raised their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a “neutral” rating in a research note on Thursday, February 19th. Finally, Leerink Partners boosted their target price on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $234.87.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.